Clarivate Epidemiology's coverage of painful diabetic neuropathy (PDN) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…
Type 2 diabetes (T2D) remains one of the biggest health challenges in China, where the prevalence of disease is globally the highest. Several traditional drug classes such as biguanides and alpha-…
Because of the dearth of targeted treatments in China, patients with relapsed/refractory (R/R) NHL, multiple myeloma, or ALL continue to be prescribed salvage chemotherapy in later lines of…
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic…
Cell therapy uses viable healthy cells to replace, expand, and/or enhance a population of cells in order to achieve a therapeutic effect against a disease. The cell therapy field is rapidly…
The type 2 diabetes (T2D) therapy market will expand over the first half of the 2020-2030 forecast period. This increase will partly be fueled by a rich pipeline of novel agents, including emerging…
The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and long treatment durations. The availability of premium-priced branded agents prescribed in…
CAR T-cell therapies have given new hope to patients with relapsed/refractory (R/R) non-Hodgkin’s lymphoma (NHL) and more recently to patients with R/R multiple myeloma. Priced at more than $350,…
Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of hematological malignancies that can be broadly classified into indolent and aggressive subtypes. The treatment algorithm for B-cell…
Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of hematological malignancies that can be broadly classified into indolent and aggressive subtypes. The treatment algorithm for B-cell…
Non-Hodgkin’s lymphoma (NHL) encompasses a plethora of subtypes with varying prognoses, and the treatment landscape is entrenched with targeted agents. Roche’s Rituxan, Janssen / AbbVie’s…
The oral type 2 diabetes (T2D) drug market is expected to grow, fueled by rising prevalence and an increasing aging population. Owing to the risk of proteinuria, cardiovascular (CV) complications,…
The type 2 diabetes therapy market will steadily expand over the 2019-2029 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the disease in…
The launch of several novel therapies and multiple label expansions of premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-year…
Metformin and sulfonylureas are the most heavily prescribed type 2 diabetes (T2D) drugs and dominate the early lines of therapy before disease progression requires insulin replacement. The…